Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: A gynecologic oncology group study

International Journal of Gynecological Pathology

Volumn 33, Issue 6, 2014, Pages 543-553

  Zaino, Richard J ^a   Brady, William E ^b   Todd, William ^a   Leslie, Kimberly ^c   Fischer, Edgar G ^d   Horowitz, Neil S ^e   Mannel, Robert S ^f,g   Walker, Joan L ^g   Ivanovic, Marina ^c   Duska, Linda R ^f  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Buffalo Niagara Enterprise   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Cancer; Carcinoma; Histology; Progestin; Response; Therapy endometrium

Indexed keywords

CASPASE 3; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR B; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; DECIDUALIZATION; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; CARCINOMA, ENDOMETRIOID; CLINICAL TRIAL; ENDOMETRIAL NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84927962321     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000177     Document Type: Article

References (26)

1. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10-4.
2. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004;92:4-9.
3. Ramirez P, Frumovitz M, Bodurka DC, et al. Hormonal therapy for the managmenet of grade 1 enodmetrial adenocarcinoma: A literature review. Gynecol Oncol 2004;95:133-8.
4. Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 1997;79:320-7.
5. Minaguchi T, Nakagawa S, Takazawa Y, et al. Combined phospho-Akt and PTEN expressions associated with posttreatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 2007;248:112-22.
6. Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 2007;22:1953-8.
7. Niwa K, Tagami K, Lian Z, et al. Outcome of fertilitypreserving treatment in young women with endometrial carcinomas. BJOG 2005;112:317-20.
8. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803.
9. Kaku T, Yoshikawa H, Tsuda H, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 2001;167:39-48.
10. Watanabe J, Watanabe K, Jobo T, et al. Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarci noma. Int J Gynecol Cancer 2006;16(suppl 1): 452-7.
11. Creasman WT, McCarty KS, Sr Barton TK, et al. Clinical correlates of estrogen- And progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 1980;55:363-70.
12. Ehrlich CE, Young PC, Stehman FB, et al. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807.
13. Geisinger KR, Marshall RB, Kute TE, et al. Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium. Cancer 1986;58:1506-17.
14. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007;31: 988-98.
15. Zaino RJ, Kurman RJ, Diana KL, et al. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 1995;75:81-6.
16. Yang S, Thiel KW, Leslie KK. Progesterone: The ultimate endometrial tumor suppressor. Trends Endocrinol Metab 2011;22:145-52.
17. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer 1959;12:1106-22.
18. Varga A, Henriksen E. Clinical and histopathologic evaluation of the effect of 17-alpha-hydroxyprogesterone-17-n-caproate on endometral carcinoma. Obstet Gynecol 1961;18:658-72.
19. Kamoi S, Ohaki Y, Mori O, et al. Serial histologic observation of endometrial adenocarcinoma treated with high-dose progestin until complete disappearance of carcinomatous foci- review of more than 25 biopsies from five patients. Int J Gynecol Cancer 2008;18:1305-14.
20. Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer 1998;83:111-21.
21. Saegusa M, Okayasu I. Down-regulation of bcl-2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinomas. J Pathol 1997;182:429-36.
22. Dahmoun M, Bäckström T, Boman K, et al. Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: results depending on methods of analysis. Int J Oncol 2003;22:115-22.
23. Utsunomiya H, Suzuki T, Ito K, et al. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. Clin Endocrinol (Oxf) 2003;58:696-703.
24. Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 1984;44:4006-10.
25. Satyaswaroop PG, Clarke CL, Zaino RJ, et al. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following down-regulation of tumor progesterone receptor. Cancer Lett 1992;62:107-14.
26. Herzog TJ. What is the clinical value of adding tamoxifen to progestins in the treatment of advanced or recurrent endometrial cancer? Gynecol Oncol 2004;92:1-3.